Movement Disorders

AbbVie recently announced a new phase 3 study (NCT04380142), called M15-736, which will measure the efficacy, safety, and tolerability of continuous subcutaneous infusion of ABBV-951.

The chief scientific officer of the Parkinson’s Foundation and adjunct associate professor in the Department of Neuroscience and Physiology at New York University School of Medicine discussed the adoption of telemedicine in Parkinson disease care.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 30, 2021.

"Mind Moments," a podcast from NeurologyLive, brings you exclusive interviews with Stephanie J. Nahas, MD; Bruce Cree, MD, PhD, MAS; Sana Somani, MD, MBBS; Hubert Fernandez, MD; Daniel Ontaneda, MD, PhD; and Richard Gershon, PhD.

A trio of clinicians from Georgetown University explore the current status of disease-modifying therapies for individuals with Parkinson disease.

The director of the Center for Neurological Restoration at Cleveland Clinic provided an inside perspective on how the MANAGE-PD tool can effectively assist in the Parkinson disease screening process.

Surgical care for PD is safe and effective, and should no longer be treated as a consideration of last resort, but as a treatment option discussed early in the disease course with the patient and their family.

Expert neurologists consider the advantages and disadvantages of oral agents for OFF time in Parkinson’s Disease such as opicapone, extended-release amantadine, and istradefylline.

Experts in Parkinson’s Disease build a discussion on the use of levodopa inhalation powder for the management of OFF time and reflect on patients’ considerations when switching therapies.

Guest Editor-in-Chief Jill Giordano Farmer, DO, MPH, shared her perspective on the importance of April as the annual Parkinson disease awareness month.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 23, 2021.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Daniel Claassen, MD, MS.

Mindy K. Bixby, DO and Laxman Bahroo, DO compare subcutaneous and sublingual apomorphine hydrochloride and discuss important factors to consider when selecting a formulation.

Experts in the management of Parkinson’s Disease OFF episodes provide insight into the sublingual formulation of apomorphine hydrochloride and discuss differences in its safety and efficacy profiles.

The chief of Movement Disorders Division at the University of Miami Miller School of Medicine discussed some of the recent focused efforts to uncover more about Parkinson disease and what is on the horizon.

In total, 50% of patients eligible for device-aided therapies did not report having any discussion with providers about future device-aided therapies.

The 2021 AAN Meeting Hot Topics plenary focused on neurological facets of COVID-19, and featured insight from Anthony Fauci, MD, of NIAID, and Walter Koroshetz, MD, of NINDS, among others.

An AAN session included presentations of research on the latest advancements and knowledge in neuromodulation for patients with these disorders.

Here's what is coming soon to NeurologyLive.

No stimulation adverse effects were reported, and patients on the MICC stimulation alone resulted in greater than 50% improvement in UPDRS motor scores.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 16, 2021.

The consultant in the Department of Neurology at Mayo Clinic discussed the mechanisms of action researchers should key in on for patients with Parkinson disease.

The 2021 AAN Annual Meeting will be held virtually from April 17-22. Follow along with coverage from NeurologyLive, including expert interviews and session recaps.

Key opinion leaders in neurology discuss the safety and efficacy of apomorphine hydrochloride and provide insights into the advantages and disadvantages of its subcutaneous formulation.

Laxman Bahroo, DO and Mindy K. Bixby, DO define OFF episodes in Parkinson’s Disease and discuss how they are often unpredictable and variable in their severity.

Overall, 42.4% of patients with Huntington disease reported at least 1 psychiatric or cognitive symptom before motor symptoms, with depression being the most common.

Here's what is coming soon to NeurologyLive.

The consultant in the Department of Neurology at Mayo Clinic discussed the advancements of Parkinson disease knowledge and treatment over the past 2 decades.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 9, 2021.